Rapyd Launches Stablecoin Payment Solutions: Digital Versatility Meets Dollar Stability
9.9.2025 14:00:00 CEST | Business Wire | Press Release
Rapyd, a leading global fintech company, today announced the launch of its Stablecoin Payment Solutions, giving businesses a secure and scalable way to accept stablecoins, settle in stablecoins and pay out using stablecoins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909572698/en/
Rapyd makes stablecoin payments seamless: Accept, settle, and pay out in one platform
2025 is the year stablecoins are moving from early-stage concept to real-world utility. Total volumes across blockchains surpassed $27 trillion1, surpassing the combined payment volumes of Visa and Mastercard in the same year2. That scale is beginning to reshape industries from gaming, to e-commerce, to traditional retail. Now, Rapyd is making it usable for enterprises in everyday payments and settlements.
Rapyd’s new suite of products addresses a central need for companies navigating volatile currencies, slow settlement times, and complex treasury operations. With Rapyd as a single provider, businesses can accept, settle, or send payouts instantly, eliminating the need for fragmented systems or multiple intermediaries. Businesses can now use Rapyd to:
- Accept Stablecoin Payments from global customers and instantly convert into preferred fiat currencies.
- Send Stablecoin Payouts securely to businesses and end users anywhere in the world, 24/7/365.
- Settle in Stablecoins to improve liquidity and reduce reliance on traditional rails like SWIFT or ACH.
“Stablecoins have moved from early-stage concept to global utility, and companies need partners who can bridge digital assets with real-world business needs,” said Arik Shtilman, CEO and Co-Founder of Rapyd. “Rapyd’s role is to strip away the complexity, integrate stablecoins into global money movement, and give businesses more control over how and when they move funds.”
The launch comes at a pivotal moment. New regulations in the US (GENIUS Act) and Europe (MiCA), along with similar initiatives in other major markets, are accelerating adoption by legitimizing stablecoins and setting clear operating standards. This regulatory clarity, combined with demand from industries such as gaming and online trading, is creating the most significant shift in financial infrastructure since the rise of card networks.
“Enterprises are under pressure to manage liquidity in real time while navigating multiple currencies and jurisdictions,” said David Rosa, General Manager of Rapyd’s Scale Business Unit. “Our Stablecoin Payment Solutions are built to remove those barriers. By combining stablecoin rails with our existing treasury, payout, and settlement infrastructure, we give CFOs and operations teams the ability to move funds instantly, reduce FX exposure, and cut out unnecessary intermediaries. It’s about taking what has been a fragmented, complex process and turning it into a single, reliable platform for global money movement.”
Rapyd’s end-to-end solution is designed for enterprises that need stability and speed in cross-border payments. For businesses operating globally, this means faster payouts. For platforms and marketplaces, it could reduce FX exposure. For the creator economy, it enables beneficiaries to receive payments with an instrument that is pegged to a currency value, even in emerging markets. By combining stablecoin rails with Rapyd’s existing global payments network, the company is positioning itself as the single provider for businesses seeking flexibility in both fiat and digital currencies.
For more information, visit: rapyd.net/solutions/stablecoin-payments
About Rapyd
Rapyd lets you build bold. Liberate global commerce with all the tools your business needs to create payment, payout and fintech experiences everywhere. From Fortune 500s to ambitious business and technology upstarts, our payments network and powerful fintech platform make it easy to pay suppliers and get paid by customers—locally or internationally.
With offices worldwide, including London, Tel Aviv, Dubai, Iceland, Amsterdam, San Francisco, Miami, Hong Kong and Singapore, we know what it takes to make cross-border commerce as easy as being next door. Rapyd simplifies payments so you can focus on building your business.
Get the tools to grow globally and learn about our products, solutions and partner programmes at www.rapyd.net. Follow: Blog, Insta, LinkedIn, Twitter.
1 Coin Telegraphcointelegraph.com/news/stablecoins-beat-visa-mastercard-2024-volume
2 CCN
Disclaimer
Rapyd’s stablecoin-related services are enabled through partnerships with regulated third-party providers. Rapyd does not itself issue, custody, or directly process crypto assets. All crypto-related services are subject to the terms, conditions, and regulatory status of Rapyd’s third-party partners. These services are delivered in collaboration with trusted third-party providers, ensuring compliance and security across all stablecoin transactions. Rapyd works with partners that adhere to applicable regulatory requirements in each jurisdiction. This Press Release is not an invitation or inducement to engage in investment activity, and does not seek to promote any such services or similar activities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909572698/en/
Contacts
Media Contact: press@rapyd.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom